These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 12442686)

  • 1. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA; Fox SH; Crossman AR; Brotchie JM
    Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
    [No Abstract]   [Full Text] [Related]  

  • 2. Functional neuroanatomy of the basal ganglia in Parkinson's disease.
    Wichmann T; DeLong MR
    Adv Neurol; 2003; 91():9-18. PubMed ID: 12442660
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson's disease is a neuropsychiatric disorder.
    Agid Y; Arnulf I; Bejjani P; Bloch F; Bonnet AM; Damier P; Dubois B; François C; Houeto JL; Iacono D; Karachi C; Mesnage V; Messouak O; Vidailhet M; Welter ML; Yelnik J
    Adv Neurol; 2003; 91():365-70. PubMed ID: 12442695
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
    Agid Y; Graybiel AM; Ruberg M; Hirsch E; Blin J; Dubois B; Javoy-Agid F
    Adv Neurol; 1990; 53():83-100. PubMed ID: 1978522
    [No Abstract]   [Full Text] [Related]  

  • 6. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L; Hellemans J
    Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.
    Whitehouse PJ
    Adv Neurol; 1987; 45():393-7. PubMed ID: 2881448
    [No Abstract]   [Full Text] [Related]  

  • 8. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 9. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
    Strange PG
    Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nondopaminergic neurons in Parkinson's disease.
    Hirsch EC; Orieux G; Muriel MP; Francois C; Feger J
    Adv Neurol; 2003; 91():29-37. PubMed ID: 12449099
    [No Abstract]   [Full Text] [Related]  

  • 14. Basal ganglia oscillations and pathophysiology of movement disorders.
    Rivlin-Etzion M; Marmor O; Heimer G; Raz A; Nini A; Bergman H
    Curr Opin Neurobiol; 2006 Dec; 16(6):629-37. PubMed ID: 17084615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 17. Pathophysiology of the basal ganglia in Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Rodríguez M; Lanciego JL; Artieda J; Gonzalo N; Olanow CW
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S8-19. PubMed ID: 11052215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the subthalamic nucleus in the pathophysiology of Parkinson's disease.
    Blandini F
    Funct Neurol; 2001; 16(4 Suppl):99-106. PubMed ID: 11996537
    [No Abstract]   [Full Text] [Related]  

  • 19. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 20. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.